908 Devices (908 Devices) ROCE %

: -16.22% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 908 Devices's annualized ROCE % for the quarter that ended in Dec. 2023 was -16.22%.

908 Devices ROCE % Historical Data

The historical data trend for 908 Devices's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-43.38

-11.87

-10.47

-14.24

-18.03

908 Devices Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %															-17.16	-22.65	-19.30	-19.30	-16.22

908 Devices ROCE % Calculation

908 Devices's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.409	/	( ( (242.587 - 19.226)	+	(202.981 - 22.549) )	/ 2 )
	=	-36.409	/	( (223.361	+	180.432)	/ 2 )
	=	-36.409	/	201.8965
	=	-18.03 %

908 Devices's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-29.724	/	( ( (208.475 - 22.322)	+	(202.981 - 22.549) )	/ 2 )
	=	-29.724	/	( ( 186.153	+	180.432 )	/ 2 )
	=	-29.724	/	183.2925
	=	-16.22 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

908 Devices (NAS:MASS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

908 Devices ROCE % Related Terms

Thank you for viewing the detailed overview of 908 Devices's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

908 Devices (908 Devices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Boston, MA, USA, 02210

Website

https://www.908devices.com

908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

Executives

Griffith Joseph H. Iv	officer: Chief Financial Officer	68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown	officer: Chief Technology Officer	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp	director, officer: President and CEO	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner	officer: VP, General Counsel	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick	officer: VP, Product Management & Mktg	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier	officer: Chief People Officer	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky	officer: Vice President, Commercial	C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg	officer: Vice President, Government	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt	director	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631